CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters
Rapid development of coronavirus disease 2019 (COVID-19) vaccines and antiviral drugs have significantly reduced morbidity and mortality worldwide. Although most of the vaccines were developed initially with the ancestral Wuhan antigen, here, we report the development and immunological efficacy of a...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1447962/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591640938676224 |
|---|---|
| author | Jyotsna Dandotiya Neeta Adhikari Manas Ranjan Tripathy Manas Ranjan Tripathy Kamini Jakhar Sudipta Sonar Dibya Ranjan Pati Vibhu Kanchan Varsha S. Prasad Jitendra Kumar Nitesh K. Senapati Arti Bharmoria Neeraj Rani Monika Lakhanpal CS. Patil Nishan Singh Lovely Khan Lavit Jambu Naveen K. Jain Syed Khalid Ali Priyanka Priyadarsiny Amulya K. Panda Rajesh Jain Shailendra Mani Sweety Samal Amit Awasthi Amit Awasthi Zaigham Abbas Rizvi Zaigham Abbas Rizvi |
| author_facet | Jyotsna Dandotiya Neeta Adhikari Manas Ranjan Tripathy Manas Ranjan Tripathy Kamini Jakhar Sudipta Sonar Dibya Ranjan Pati Vibhu Kanchan Varsha S. Prasad Jitendra Kumar Nitesh K. Senapati Arti Bharmoria Neeraj Rani Monika Lakhanpal CS. Patil Nishan Singh Lovely Khan Lavit Jambu Naveen K. Jain Syed Khalid Ali Priyanka Priyadarsiny Amulya K. Panda Rajesh Jain Shailendra Mani Sweety Samal Amit Awasthi Amit Awasthi Zaigham Abbas Rizvi Zaigham Abbas Rizvi |
| author_sort | Jyotsna Dandotiya |
| collection | DOAJ |
| description | Rapid development of coronavirus disease 2019 (COVID-19) vaccines and antiviral drugs have significantly reduced morbidity and mortality worldwide. Although most of the vaccines were developed initially with the ancestral Wuhan antigen, here, we report the development and immunological efficacy of a whole-virion–inactivated vaccine candidate (CoviWall) to combat the deadly B.1.617.2 (Delta strain) infection. In the current study, we demonstrate a consistent manufacturing process under Good Manufacturing Practice for the development of CoviWall and its characterization using various analytical methods as per regulatory compliance. In addition, we provide pre-clinical immunogenicity and protective efficacy data of the CoviWall vaccine. All the three test doses (i.e., low dose, mid dose, and high dose) immunized in C57BL/6 mice elicited a high titer of anti–receptor-binding domain antibody and neutralizing antibody response against severe acute respiratory syndrome coronavirus–2 (SARS-CoV-2) after second booster dose. In addition, CoviWall immunization also produced a significant T-cell response in the immunized animals. Our B.1.617.2 strain challenge data in Syrian hamsters indicate that immunized hamsters show attenuated clinical manifestations of COVID-19 with reduced lung viral load. Moreover, assessment of pulmonary histopathology revealed lower cellular injury, inflammation, and pneumonia in the vaccinated hamsters as compared to the unvaccinated animals. Such promising results augur well for the clinical phase I trial of the CoviWall vaccine and further development against contagious SARS-CoV-2 strains in the future. |
| format | Article |
| id | doaj-art-156fd1dc915a4158a1eeba37e50fb99c |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-156fd1dc915a4158a1eeba37e50fb99c2025-01-22T07:12:55ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.14479621447962CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamstersJyotsna Dandotiya0Neeta Adhikari1Manas Ranjan Tripathy2Manas Ranjan Tripathy3Kamini Jakhar4Sudipta Sonar5Dibya Ranjan Pati6Vibhu Kanchan7Varsha S. Prasad8Jitendra Kumar9Nitesh K. Senapati10Arti Bharmoria11Neeraj Rani12Monika Lakhanpal13CS. Patil14Nishan Singh15Lovely Khan16Lavit Jambu17Naveen K. Jain18Syed Khalid Ali19Priyanka Priyadarsiny20Amulya K. Panda21Rajesh Jain22Shailendra Mani23Sweety Samal24Amit Awasthi25Amit Awasthi26Zaigham Abbas Rizvi27Zaigham Abbas Rizvi28Immuno-biology Lab, Centre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, Near Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, IndiaImmuno-biology Lab, Centre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, Near Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, IndiaImmuno-biology Lab, Centre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, Near Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, IndiaImmunology-Core Lab, Translational Health Science and Technology Institute, Near Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, IndiaOneStream Research Centre, Panacea Biotec Limited, New Delhi, IndiaOneStream Research Centre, Panacea Biotec Limited, New Delhi, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaTranslational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, IndiaOneStream Research Centre, Panacea Biotec Limited, New Delhi, IndiaOneStream Research Centre, Panacea Biotec Limited, New Delhi, IndiaImmuno-biology Lab, Centre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, Near Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, IndiaImmunology-Core Lab, Translational Health Science and Technology Institute, Near Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, IndiaImmuno-biology Lab, Centre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, Near Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, IndiaImmunology-Core Lab, Translational Health Science and Technology Institute, Near Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, IndiaRapid development of coronavirus disease 2019 (COVID-19) vaccines and antiviral drugs have significantly reduced morbidity and mortality worldwide. Although most of the vaccines were developed initially with the ancestral Wuhan antigen, here, we report the development and immunological efficacy of a whole-virion–inactivated vaccine candidate (CoviWall) to combat the deadly B.1.617.2 (Delta strain) infection. In the current study, we demonstrate a consistent manufacturing process under Good Manufacturing Practice for the development of CoviWall and its characterization using various analytical methods as per regulatory compliance. In addition, we provide pre-clinical immunogenicity and protective efficacy data of the CoviWall vaccine. All the three test doses (i.e., low dose, mid dose, and high dose) immunized in C57BL/6 mice elicited a high titer of anti–receptor-binding domain antibody and neutralizing antibody response against severe acute respiratory syndrome coronavirus–2 (SARS-CoV-2) after second booster dose. In addition, CoviWall immunization also produced a significant T-cell response in the immunized animals. Our B.1.617.2 strain challenge data in Syrian hamsters indicate that immunized hamsters show attenuated clinical manifestations of COVID-19 with reduced lung viral load. Moreover, assessment of pulmonary histopathology revealed lower cellular injury, inflammation, and pneumonia in the vaccinated hamsters as compared to the unvaccinated animals. Such promising results augur well for the clinical phase I trial of the CoviWall vaccine and further development against contagious SARS-CoV-2 strains in the future.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1447962/fullCoviWallCOVID-19-vaccineimmunogenicityhamsterDelta strainTh1 |
| spellingShingle | Jyotsna Dandotiya Neeta Adhikari Manas Ranjan Tripathy Manas Ranjan Tripathy Kamini Jakhar Sudipta Sonar Dibya Ranjan Pati Vibhu Kanchan Varsha S. Prasad Jitendra Kumar Nitesh K. Senapati Arti Bharmoria Neeraj Rani Monika Lakhanpal CS. Patil Nishan Singh Lovely Khan Lavit Jambu Naveen K. Jain Syed Khalid Ali Priyanka Priyadarsiny Amulya K. Panda Rajesh Jain Shailendra Mani Sweety Samal Amit Awasthi Amit Awasthi Zaigham Abbas Rizvi Zaigham Abbas Rizvi CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters Frontiers in Immunology CoviWall COVID-19-vaccine immunogenicity hamster Delta strain Th1 |
| title | CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters |
| title_full | CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters |
| title_fullStr | CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters |
| title_full_unstemmed | CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters |
| title_short | CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters |
| title_sort | coviwall a whole virion inactivated b 1 617 2 vaccine candidate induces potent humoral and th1 cell response in mice and protects against b 1 617 2 strain challenge in syrian hamsters |
| topic | CoviWall COVID-19-vaccine immunogenicity hamster Delta strain Th1 |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1447962/full |
| work_keys_str_mv | AT jyotsnadandotiya coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT neetaadhikari coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT manasranjantripathy coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT manasranjantripathy coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT kaminijakhar coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT sudiptasonar coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT dibyaranjanpati coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT vibhukanchan coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT varshasprasad coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT jitendrakumar coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT niteshksenapati coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT artibharmoria coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT neerajrani coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT monikalakhanpal coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT cspatil coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT nishansingh coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT lovelykhan coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT lavitjambu coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT naveenkjain coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT syedkhalidali coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT priyankapriyadarsiny coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT amulyakpanda coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT rajeshjain coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT shailendramani coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT sweetysamal coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT amitawasthi coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT amitawasthi coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT zaighamabbasrizvi coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters AT zaighamabbasrizvi coviwallawholevirioninactivatedb16172vaccinecandidateinducespotenthumoralandth1cellresponseinmiceandprotectsagainstb16172strainchallengeinsyrianhamsters |